Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares in the company, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $66.28 on Friday. The business has a fifty day moving average price of $34.66 and a two-hundred day moving average price of $25.48. The stock has a market capitalization of $14.48 billion, a PE ratio of 150.64 and a beta of 1.35. Hims & Hers Health, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $72.98.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HIMS. TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler lifted their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average target price of $28.53.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HIMS. Vanguard Group Inc. lifted its position in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.